When does the liraglutide patent expire?
Liraglutide's primary patents have expired, meaning generic versions of the drug can now be developed and marketed [1]. The earliest patents for liraglutide began expiring around 2023 [1][2].
What is liraglutide used for?
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is prescribed to improve glycemic control in adults with type 2 diabetes mellitus [3]. It is also used for chronic weight management in adults and adolescents aged 10 years and older who have obesity or are overweight with at least one weight-related condition [3].
How does liraglutide work?
As a GLP-1 receptor agonist, liraglutide mimics the action of the natural hormone GLP-1. This hormone is released after meals and plays a role in regulating appetite and blood glucose levels. Liraglutide works by increasing insulin secretion, reducing glucagon secretion, and slowing gastric emptying, all of which contribute to lowering blood sugar [3][4]. It also acts on appetite control centers in the brain to reduce food intake [4].
Who makes liraglutide?
Liraglutide is marketed by Novo Nordisk under brand names such as Victoza (for diabetes) and Saxenda (for weight management) [3].
What are the risks associated with liraglutide?
Common side effects of liraglutide include nausea, vomiting, diarrhea, constipation, and abdominal pain [3]. More serious risks include pancreatitis, gallbladder problems, and a potential increased risk of thyroid C-cell tumors, though this has primarily been observed in rodent studies and the relevance to humans is not fully understood [3][5].
What is the difference between Victoza and Saxenda?
Both Victoza and Saxenda contain the active ingredient liraglutide. The key difference lies in their approved indications and dosage strengths. Victoza is approved for the treatment of type 2 diabetes, while Saxenda is approved for chronic weight management [3][6]. Saxenda is administered at a higher dose than Victoza [6].
Can biosimilars of liraglutide be developed?
With the expiration of primary patents, the development of biosimilar versions of liraglutide is possible [1]. Biosimilars are highly similar to approved biologic medicines and are intended to offer a more affordable treatment option once patents expire and regulatory pathways are established [7].
What is the status of liraglutide patent litigation?
Information on ongoing or past patent litigation specifically for liraglutide can be found through specialized patent tracking resources like DrugPatentWatch.com [1]. Such litigation often involves disputes over patent validity or alleged infringement.
How does liraglutide compare to other GLP-1 receptor agonists?
Other GLP-1 receptor agonists include drugs like semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon). These drugs share similar mechanisms of action but may differ in their dosing frequency, efficacy, side effect profiles, and approved indications [4][8]. For instance, semaglutide has shown higher efficacy in both glycemic control and weight loss compared to liraglutide in some studies [8].
What is the price of liraglutide?
The price of liraglutide can vary significantly based on factors such as dosage, quantity, insurance coverage, and pharmacy. As patents expire, the introduction of generic versions is expected to lead to price reductions [1][7].
Sources:
[1] https://drugpatentwatch.com/
[2] https://drugpatentwatch.com/liraglutide/patent
[3] https://www.ncbi.nlm.nih.gov/books/NBK542178/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795387/
[5] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021941s030,204790s011lbl.pdf
[6] https://www.novomedlink.com/products/saxenda/hcp.html
[7] https://www.fda.gov/drugs/biosimilars/about-biosimilars
[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647908/